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Hepatitis B virus (HBV) infection has been a major global cause of morbidity and mortality. The recognition of the problem led to 
a worldwide effort to reduce transmission of HBV through routine infant vaccination. HBV infection is the most common cause of 
chronic liver diseases and hepatocellular carcinoma in Korea. After hepatitis B vaccine era, seroprevalence of hepatits B surface 
antigen is decreasing, particularly in children. Hepatitis B vaccine is remarkably safe and shows high immunogenicity. Universal 
childhood immunization with three doses of hepatitis B vaccine in the first year of life is a highly effective method for prevention 
and control of hepatitis B. (Korean J Hepatol 2011;17:87-95)
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INTRODUCTION
Hepatitis B is an infectious disease, associated with an 
estimated 350 million chronically infected patients.
1 Perinatal 
transmission is an important cause of hepatitis B virus 
(HBV) transmission, account for 35% to 50% of HBV 
carriers.
2  Korea is an endemic area of HBV infection, 
therefore, hepatitis B is an important public health problem. 
This review describes an overview of HBV infection, 
epidemiology, immunization, and prevention.
HEPATITIS B VIRUS
HBV is a 42-nm DNA virus in the family Hepadnaviridae. 
The virus has a partially double-stranded DNA with core 
antigen surrounded by a shell containing surface antigen 
(HBsAg).
3 HBV contains numerous antigenic components, 
including HBsAg, HBcAg, and hepatitis B e antigen 
(HBeAg). The HBV genome has 3200 nucleotides, and it 
efficiently uses its genetic information to encode four groups 
of proteins and their regulatory elements by shifting the 
reading frames over the same genetic material.
4 The immune 
response to HBsAg provides the immunity against HBV. 
Antibodies to HBcAg indicate infection, IgM anti-HBc 
indicates recent infection and usually disappears within six 
months, while IgG anti-HBc persists for life and indicates 
past infection. Antibody to HBsAg (anti-HBs) appears after 
clearance of HBsAg or after immunization. The presence of 
HBsAg for more than six months is defined as chronic HBV 
infection.
MODE OF TRANSMISSION
HBV is transmitted parenterally by contaminated blood or 
other body fluids through blood vessels, skin or mucous 
membranes. The virus can be detected in all human body 
fluids, the virus concentration in the fluids is highest in the 
blood or serous exudates, and it is relatively low in saliva, 
semen, vaginal fluids.
5 Thus, there is almost no risk of 
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through fecal-oral transmission does not occur.
The main transmission routes include perinatal infection, 
the skin and mucous membrane infections caused by 
contaminated blood or body fluids (blood transfusion, use of 
contaminated syringes, hemodialysis, invasive tests or 
surgery), and sexual contacts. In Korea, the most important 
route is perinatal transmission in patients with chronic 
hepatitis B.
6 
Perinatal infection occurs frequently if the mother with 
HBV is HBeAg-positive and has a high level of serum 
HBV-DNA. If infants born to HBsAg-positive mother do not 
receive perinatal hepatitis B vaccine and immunoglobulin 
prophylaxis, infection rates in infants born to HBsAg 
positive and negative mother are 70 to 90% and 10 to 20%, 
respectively, of which 90% will progress to chronic 
infection.
7,8 When given with vaccine and immunoglobulin 
within 24 hours after birth, 90% of infants show the 
preventive effect.
9 Although a very small amount of HBV is 
detected in breast milk, there is no evidence that hepatitis B 
is transmitted through breast milk.
In injection drug abuser, using the same syringe among 
injection drug users at the same time is the main trans-
mission route of hepatitis B infection.
10 In addition, 
tattooing, ear piercing, acupuncture, dialysis, and even using 
a syringe can be the source of infection.
11
In adolescents and adults in the countries with low and 
middle prevalence rates of hepatitis B, sexual contact is the 
major cause of HBV infection.
12 Recently, as the prevalence 
of HBV infection is decreasing in young adult age group in 
Korea, the sexual contact has become the main transmission 
route.
CLINICAL FEATURES
Hepatitis B shows variable clinical manifestations ranging 
from asymptomatic HBV carriers to fulminant liver failure, 
and it becomes chronic, often progresses to chronic hepatitis, 
cirrhosis, and hepatocellular carcinoma.
13 These clinical 
manifestations may vary depending on their age at infection, 
showing symptoms in less than 10% of children under 5 
years old, while causing symptoms of the infection in 30 to 
50% in adults.
14 The risk of chronic HBV infection varies 
inversely with age; 80 to 90% of neonatal infections, 30 to 
60% of infants, 5% or less of adults.
15 The majority of cases 
of vertical transmission from mother progresses to chronic 
carriers.
The incubation period for the onset of acute hepatitis B is 
3 to 4 months, showing prodromal symptoms such as 
fatigue, fever and anorexia, which are similar to other viral 
hepatitis. Serum-sickness syndromes such as joint pain and 
rash were observed in about 10% of patients.
16 Jaundice 
occurs at 1 or 2 weeks after the onset of symptoms, and 
clinical symptoms are improved in the majority of cases 
within 3 months. Fulminant hepatitis, accompanied by 
hepatic encephalopathy is complicated in 0.5% of cases in 
adult patients.
17 In most cases of acute hepatitis B, HbsAg 
disappears within 6 months and liver function is recovered. 
When the virus persists longer than 6 months, it becomes a 
chronic state. The natural history of chronic hepatitis B is 
determined by the immune response and viral replication. 
The initial phase of perinatally acquired infections is 
characterized by high levels of virus replication with no 
evidence of active liver disease with normal transaminase 
levels due to immune tolerance.
18 The second phase of 
perinatally acquired chronic infection, immune clearance 
phase, is characterized by high levels of virus replication 
with active liver disease. Fibrosis of the liver can develop 
during this phase, which can lead to cirrhosis. During the 
immune clearance phase, seroconvesion of HBeAg and 
decrease in HBV DNA level may occur, hereafter staying as 
'inactive HBV carriers' with low viral load and normal liver 
function.
19 Some patients show repeated increase in virus 
levels and necroinflammation, progressing to cirrhosis or 
liver cancer over a long period of time.
20 The clinical course 
of hepatitis B is determined by the interaction of viral 
replication status and host immune response. Otherwise, 
it can be worsened by the factors such as alcohol and 
coinfection with other viruses. The risk of progression to 
decompensated liver disease or the incidence of liver cancer 
increases with high viral replication status and the risk is 
higher in patients with cirrhosis than hepatitis.
21 It has been 
known that the risk of liver cancer is increased further in 
patients with older age, family history of liver cancer or 
cirrhosis, alcohol and the coinfection of hepatitis C virus.
22
EPIDEMIOLOGY 
Hepatitis B is the most common and important cause of 
cirrhosis and hepatocellular carcinoma in Korea, accounting 
for approximately 70% of the causes.
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HBV is infected by parenteral route through blood or body 
fluids. In the past, blood transfusions were the mainstream 
infections, but now there are almost no infections due to the 
introduction of screening tests for HBV in blood donors and 
vaccinations. In the areas with high prevalence rate of HBV 
as in Korea, perinatal transmission from mother to child is 
the major route of infection.
24 In addition, infections through 
sexual transmission or needle sharing are possible trans-
mission route in adults.
Until the 1980s before the introduction of hepatitis B 
vaccine in Korea, the prevalence rate of HBV was almost 
8% of the general population.
25 Perinatal infection rate and 
intrafamily infections were very high in the infant and 
childhood.
26  Hepatitis B vaccination was introducted in 
Korea since 1985, and immunization for all neonates and the 
active and passive immunization for newborns of HBsAg 
positive mothers have been performed since 1991. After 
vaccine era, the prevalenc of HBV infection in Seoul metro-
politan area was markedly reduced to 0.6% in children under 
10 years old, to about 1.6% in the teens, and also it was 
reduced to 3% in the early 20s.
27 However, the prevalenc rate 
in 20s and over showed 7.6% in men and 3.4% in women, 
respectively, indicating no significant differences to the 
prevalence rates in the past. Perinatal infection in HBV 
carriers was also as high as 54.7% in age 20 and over, while 
it was reduced to 7.4% in age less than 10.
28 Hepatitis B 
vaccine has been included in a National Immunization 
Program, and since 95% of infants are vaccinated, the 
neonatal hepatitis B prevention in Korea is being imple-
mented effectively.
29 Recently, the HBsAg positive rate for 
those under school age is very low at less than 1%.
30 Twenty 
years after the introduction of the vaccine, the prevalence of 
HBV infection is decreasing in adolescence and young 
adults as well as in the ages of infants and children. A 
nationwide sero-epidemiological survey is needed to provide 
immunization strategies in adult population.
The occurrence of acute hepatitis B also decreased, and in 
recent years, it became rarely observed in age groups under 
20.
31 The phenomenon of the decrease in young patients 
with acute hepatitis B is similar to other countries such as 
Taiwan or the United States, and it is consistent with the time 
for introduction of hepatitis B vaccination.
32-34 The reduced 
incidence of acute hepatitis B in youth ultimately implies the 
reduced incidence of acute hepatitis B infection for the 
society or country as a whole. On the other hand, the 
incidence of acute hepatitis B in the age group over 30 years 
is relatively high compared to the younger age groups, 
which might be due to many unvaccinated people.
31 
EFFICACY OF HEPATITIS B VACCINE
The ultimate goal of hepatitis B vaccination is to reduce 
the prevalence of chronic hepatitis B carriers, as well as to 
prevent the occurrence of acute hepatitis B. Vaccination is 
the most effective method for the decrease in the prevalence 
of HBV infection. 
Hepatitis B vaccines have been evaluated in clinical trials 
to determine protective level of serum anti-HBs. Persons 
who respond to HBV vaccine with titers of anti-HBs 10 
mIU/mL or greater are protected against acute hepatitis B 
and chronic infection.
35 Antibody production rate is higher 
in the younger age at vaccination and lower for those older 
than 40 years of age. Thus, antibody test after vaccination is 
not required for healthy people, however, it should be tested 
after vaccination in hemodialysis patients, HIV positive 
people, those at occupational risk of infection such as 
workers in operation rooms and intensive care unit, babies 
born to HBsAg-positive mothers, and those with family 
history of HBV carriers. Since the antibody titer is at 
maximum around on 1 to 3 months after the completion of 
vaccine series, the tests for anti-HBs are performed at this 
time.
The antibody response to hepatitis B vaccine is 90% in 
healthy adults and 95% of infants, children, and adolescents.
36 
As for vaccine efficacy, complete protection has been 
achieved among immunocompetent persons who developed 
anti-HBs titers of 10 mIU/mL or greater after completion of 
vaccination.
35,37
Long-term follow-up studies of newborn vaccination 
demonstrated that antibodies become negative in 15-50% 
among the vaccine responders within 5 to 10 years.
33,38,39 In 
adults, antibodies become negative in 7-50% within 5 years, 
and 30-60% within 10 years.
39,40 In the cohort study for 20 
years after infant vaccination, booster vaccination in cases 
of waning antibody produced antibody response rate in 
excess of 80%, and HBV infection did not occur during the 
period of the cohort.
41 The persistent protection against 
clinically significant hepatitis B despite of declining anti-
body titers is an anamnestic immune response after HBV 
exposure.
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able to respond rapidly to HBV infection. At present, routine 
booster doses of hepatitis B vaccine or periodic serologic 
test to monitor antibody titiers for immune-competent 
persons who have responded to vaccination is not recom-
mended.
43 However, additional vaccinations are required for 
immunocompromised patients such as patients with chronic 
renal failure if antibodies become negative in antibody 
testing every year after vaccination.
44  Persons who have 
anti-HBs titer after completion of primary vaccine series 
less than 10 mlU/mL is called ‘vaccine nonresponders’. 
Several factors has been associated with nonresponse to 
HBV vaccination. These include inappropriate vaccine 
storage conditions, vaccination in buttocks, old age, obesity, 
hemodialysis, chronic liver disease, and state of immuno-
suppression, and presence of DR3, DR7 DQ2 and absence of 
A2 alleles.
45,46 Approximately 5-10% of vaccinated person 
do not achieve detectable antibody response (nonresponders).
47 
Further vaccination of the nonresponders administered in 
the deltoid muscle produces adequate antibody response in 
15% to 25% of them after one additional dose and in 30% to 
50% after three additional doses.
48
There are several approaches to improve the antibody 
response to vaccine. Obesity can be a major cause of 
lowering the rate of antibody production by the vaccine, 
recently it has been reported that antibody titers were raised 
by using long needles.
49 The research for developing new 
vaccines to improve immunity of the vaccine also has been 
actively conducted. The vaccines including the Pre-S antigen 
produced by recombinant DNA methods using CHO cells, 
or Fendrix
® containing MPL (3-O-desacyl-4- monophosphoryl 
lipid A) as an additive to conventional vaccine components 
can increase the reaction of antibody generation by the 
vaccine and continue the immune response.
50 In addition, 
the method to reduce the number of vaccinations to two 
times in order to increase vaccination rates and compliance 
of vaccination, various forms of combination vaccines 
containing HBV components have been developed and 
currently the combination vaccines with HAV, DTP or Hib 
have been used.
51,52 Hepatitis B vaccine has no significant 
increase in adverse reactions and no interference in antiobody 
response of other immunizations such as DPT, polio, 
measles, Hib, or hepatitis A.
53,54  In addition, even when 
vaccinated with other types of hepatitis B vaccination after 
a hepatitis B vaccines, there is no difference in vaccine 
effectiveness. In recent years, the vaccination methods 
through skin or mucous membranes other than traditional 
intramuscular injection have been introduced by developing 
new antigen delivery systems.
55
Hepatitis B vaccination decreases HBV infection and 
ultimately reduce the incidence of chronic liver disease or 
liver cancer. It was reported that incidence of hepatocellular 
carcinoma in children decresed more than 50% after universal 
infant and childhood vaccination.
56 In Korea, neonatal 
vaccination has been conducted and HBsAg positive rate in 
young adults have recently been greatly reduced, showing 
only about 3% of HBV infection rate, and it has been 
decreased less than 1% in children.
27 The incidence of acute 
hepatitis B has been also reduced, therefore, the incidence of 
chronic liver diseases or hepatocellular carcinoma by HBV 
infection could be expected to decrease in the future.
PREVENTION
Preventive measures of HBV infection include the avoidance of 
high-risk behaviors, the prevention of exposure to blood and body 
fluids, the screening of women in pregnancy for HBV, active 
immunization or passive immunization before or after exposure. 
There are active immunization method using vaccines and passive 
immunization with HBIG. 
Active immunization
Types of vaccines
Plasma vaccines isolated from HBV carriers have been 
used since 1980s. The plasma vaccines were developed in 
the early days of vaccines in Korea, and plasma vaccines 
was used from 1983.
57 Plasma vaccines produce good 
immunogenecity and they are effective and safe. However, 
they are rarely used in recent years due to the shortage of 
plasma of HBsAg carriers, the concerns for the safety of 
blood product, and the development of recombinant DNA 
technology. Recombinant DNA vaccines are produced by 
introducing HBsAg into yeast or mammalian cells (CHO; 
Chinese Hamster Ovary cell).
58 Antibody conversion rates 
and geometric means of the generated antibody titers by 
recombinant vaccines are similar to the plasma vaccines.
36
Combination vaccines containing a hepatitis B vaccine 
component are developed. These include DTP-HepB vaccine, 
DTP-Hib-HepB vaccine, DTP-Hib-inactivated poliovirus 
vaccine-HepB vaccine, Hib-HepB vaccine, and hepatitis 
A-HepB vaccine.
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Table 1. Groups of high risk for hepatitis B virus infection
Homosexually active men
Persons at high risk of sexually transmitted HBV infection
Injection drug user
Household members and sexual partner of HBV carriers
Clients and staffs in mental health institutions
Patients of hemodialysis units
Extended travel to areas of high endemicity
Patients who receive clotting factor concentrates
Persons at occupational risk of HBV infection
Vaccine dose and method
Hepatitis B vaccine includes 20 μg of surface antigen for 
adults, and 10 μg for children. The vaccine should be given 
by intramuscular injection in anterolateral aspect of thigh of 
infants and children less than 2 years of age, and in the 
deltoid muscle of older children, adolescents, and adults. 
Injection in the buttocks is not recommended because of the 
possibility of subcutaneous inoculation into deep fat tissue, 
which is associated with decreased protective antibody 
levels.
59  There is no interference effect of simultaneous 
vaccination with any other vaccines, and in this case, 
injection site should be in other parts or at least 1.5 cm apart 
from the hepatitis B vaccine inoculation site.
Hepatitis B vaccine is generally administered in three 
doses, with the second dose given one month after the first 
dose and the third dose given six months after the first dose. 
Vaccines from the other manufactures can be used inter-
changeably. If the series is interrupted after the first dosem 
the second dose should be given as soon as possible and the 
second and third doses should be separated by an interval of 
at least 2 months. If the third dose is delayed, it should be 
given as soon as possible. It is not necessary to restart the 
vaccine series when there has been prolonged interval 
between the doses.
60,61 
Vaccination shall be given at 0, 1, and 6-month intervals. 
A second vaccination shall be given at one month after the 
first vaccination, and in case of missing the vaccination 
schedule, without having to start again, it shall be given right 
away, and a third vaccination shall be given at the interval of 
two months or more after second vaccination.
Storage and safety of vaccines
Most hepatitis B vaccines should be kept in 2-8℃ storage 
temperatures, and the efficacy is maintained at least 4 years. 
Vaccine efficacy is maintained at room temperature and can 
be stored for up to one year. Vaccine should not be frozen 
because the freezing causes the HbsAg protein to dissociate 
from the alum adjuvant and lose immungenicity.
62
Serologic testing 
Serologic testing is not indicated before routine vaccination 
of infants or children. Screening test in adults is considered 
in the endemic area of HBV infection or in the groups with a 
high risk of HBV infection. Serologic test following vaccination 
in healthy adults is not recommended. However, antibody 
tests should be considered in health care workers who are at 
the high risk of infection or in the cases of hemodialysis 
patients, HIV-infected patients, and spouses of hepatitis B 
patients. Post-vaccination testing should be performed 1-2 
months after completion of the vaccine series. 
Vaccine non-responder
Anti-HBs response less than 10 mIU/mL after completion 
of the first vaccine series is called 'nonresponders'. 
Re-vaccination is recommended in the nonresponders. 
Administration of a single dose of vaccine, followed by 
measurement of anti-HBs antibody response 1-3 months 
later to differentiate anamnestic response. For persons who 
are seronegative after the booster dose, a second vaccine 
series of two additional doses, which result in seroconversion 
in 50 to 60% of recipients.
48 Generally, additional vaccination 
is not recommended to the complete nonresponders who do 
not achieve the appropriate antibody level even after a total 
of 6 times of vaccinations. HBIG should be administered 
when they are exposed to HBV. 
Adverse reactions
Hepatitis B vaccine is safe and mild side effects appear 
within 24 hours, showing fever in 1-6%, injection site pain 
in 3-29%, redness and mild swelling in 3%, and headache in 
3%.
63,64 Arthritis, multiple sclerosis, diabetes, Guillain-Barre 
syndromes have no direction association to the hepatitis B 
vaccination.
65 Hypersensitivity to vaccine components, such 
as yeast, can cause anaphylaxis.
66 
Indications
Comprehensive HBV immunization strategies prevent 
chronic HBV infection acquired in all age groups. In the 
past, vaccination to all newborns was performed mainly in 
the hepatitis B prevalent areas, but since 1997, hepatitis B 92  The Korean Journal of Hepatology Vol. 17. No. 2, June 2011
Table 2. Recommendations for postexposure immunoprophylaxis following exposure to hepatitis B virus
Status of exposed person
Status of source
HBsAg positive HBsAg negative Unknown
Unvaccinated HBIG (1 dose) and HBV 
vaccination
HBV vaccination HBV vaccination
Vaccinated
  Responders
* No treatment No treatment No treatment
  Nonresponders HBIG (1 dose) and HBV 
revaccination (3 doses)
No treatment
Revaccination (3 doses) for future 
protection
If high-risk source, HBIG (1 dose) 
and HBV revaccination (3 doses)
Response unknown Test anti-HBs
- if positive, no treatment
- if negative, HBIG (1 dose) 
and HBV vaccination (3 doses)
No treatment Test anti-HBs
- if positive, no treatment
- if negative, HBIG (1 dose) and 
HBV revaccination (3 doses)
* Responders is a person with anti-HBs titer 10 mIU/mL or greater after completion of primary vaccine series.
HBIG, hepatitis B immune globulin.
vaccinations to newborns are being performed worldwide 
regardless of the prevalence of hepatitis B. Currently, 
vaccinations to all newborns are being performed and even 
in adults, catch-up vaccination is recommended in case of 
unvaccinated person without anti-HBs.
43,54 It should be 
particularly recommended to high-risk groups of hepatitis B 
(Table 1).
67
Contraindications
The vaccination is contraindicated in those who have a 
history of hypersensitivity to vaccine components or who 
have experienced severe side effects after the hepatitis B 
vaccination previously. There is limited data on the safety of 
hepatitis B vaccine for pregnant woman, however, there is 
no apparent adverse effect to fetus. Therefore, pregnancy or 
breast feeding are not a contraindication to vaccination.
68 
The vaccine can be given to immunocompromised patients, 
but the antibody response to the vaccination is lower than in 
healthy people.
69
Passive immunization
Hepatitis B vaccination not only prevents hepatitis B but 
also can attenuate the severity of illness or inhibit the 
progress toward chronic phase even if they have already 
been infected and in the incubation period during vaccination. 
HBIG is recommended for postexposure prophylaxis in the 
setting of perinatal exposure, percutaneous or mucous 
membrane exposure to HBV, and sexual exposure to an 
HBV carrier. It is also used to reduce the risk of recurrent 
HBV infection after liver transplantation.
70 HBIG is prepared 
from human plasma of those who contain a high titer of 
anti-HBs. HBIG is effective in preventing clinical hepatitis 
B or chronic infection, if used shortly after exposure to 
HBV.
71
One of the major uses of HBIG is as an immuonpro-
phylaxis in preventing perinatal HBV transmission. It has 
been reported that immunoprophylaxis with both HBIG and 
hepatitis B vaccine could increase the efficacy of preventing 
perinatal HBV transmission to 85% to 95% and provide 
long-term protection.
72-73 HBIG in indicated for postexposure 
prophylaxis after needle stick injury or percutaneous 
exposure. In cases of the percutaneous and mucosal exposure 
to blood or body fluids, such as HBsAg-positive needle 
stick, the prophylactic procedures vary depending on the 
vaccination status of the exposed person and the status of 
antibody. The persons who have anti-HBs after vaccination 
do not need the vaccine or HBIG. In unvaccinated cases, 
HBIG 0.06 mL/kg, up to 5 mL is given by intramuscular 
injection. and the first dose of vaccine should be given 
within 24 hours after exposure (Table 2). In nonresponders, 
restart the vaccination after the injection of HBIG immediately. 
In nonresponders who did not complete re-vaccination after 
the primary vaccination, it is better to start again after 1 time 
of HBIG injection. In nonresponders even after 3 times of 
re-vaccination, it is preferred to perform 2 times of HBIG 
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General measures
HBV is mainly transmitted through perinatal infection, 
sexual contact, blood, and contaminated needles from drug 
abusers. It can be transmitted through the direct contacts or 
skin wounds between patients and surgeons or dentists, or 
indirectly through hemodialysis, razors, toothbrushes, and 
acupuncture therapy.
32 After exposure to HBV contaminated 
blood or body fluids, HBV contaminated blood should be 
removed and disinfect the contaminated instruments. In 
addition, education on the transmission routes to the public 
and the medical workers are needed for the prevention of 
HBV infection.
CONCLUSIONS
Hepatitis B immunization has made a hepatitis B a vaccine 
preventable infectious disease. The hepatitis B vaccine has 
been associated with decrease in the incidence of HBV 
infection, and ultimately reduced chronic liver diseases and 
hepatocellular carcinoma related to HBV infection. Universal 
vaccination program of infants and children has been 
successfully control the HBV infection in endemic areas 
including Korea. We also should pay attention to the 
prevention of perinatal transmission and HBV infection in 
unvaccinated adults.
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